Status:

TERMINATED

RNA Precision Oncology in Advanced Pancreatic Cancer

Lead Sponsor:

Columbia University

Conditions:

Pancreatic Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The overall objective of this project is to determinate the feasibility of administering personalized therapy to subjects with advanced pancreatic cancer utilizing the novel OncoTreat platform. The pr...

Detailed Description

Pancreatic ductal adenocarcinoma (PDA) is a major health problem in the United States and throughout the world. Pancreatic ductal adenocarcinoma (PDA) has the worst prognosis of any major malignancy i...

Eligibility Criteria

Inclusion

  • Be willing and able to provide written informed consent for the trial.
  • Age ≥18 years of age on day of signing informed consent.
  • Have histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma or be willing to undergo a biopsy with confirmed pathology prior to starting therapy.
  • Have untreated disease that is unresectable due to being metastatic or locally advanced without potential of surgery as assessed by the treating physician.
  • Subjects who have documented disease recurrence greater than 6 months after completing neoadjuvant or adjuvant chemotherapy for limited disease will be eligible for the study.
  • Have a predicted life expectancy of greater than 6 months.
  • Subjects must have a plan to obtain a new core biopsy of a primary and/or metastatic lesion planned as part of routine care for which consent is obtained separately or (b) consent to be biopsied to satisfy the tissue requirements of this protocol.

Exclusion

  • Has previously received neoadjvuant or adjuvant chemotherapy for pancreatic cancer unless greater than 6 months has passed since completion of adjuvant or neoadjuvant chemotherapy and initiation of therapy for recurrent or metastatic disease.

Key Trial Info

Start Date :

December 7 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 31 2023

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT04476537

Start Date

December 7 2020

End Date

March 31 2023

Last Update

April 3 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Columbia University Irving Medical Center

New York, New York, United States, 10032